Researchers at the University of Pennsylvania, Sheri Yang and Michael Mitchell, have been awarded a $2.79 million grant from the National Institutes of Health (NIH) to study a novel treatment for rheumatoid arthritis (RA). The project aims to develop targeted drug delivery systems that can reduce inflammation and joint damage, potentially offering a more effective and safer alternative to current treatments.
The research will focus on creating nanoparticles that specifically target immune cells involved in the pathogenesis of RA. By delivering therapeutic agents directly to these cells, the researchers hope to minimize systemic side effects and enhance treatment efficacy. Current treatments for RA often involve broad immunosuppression, which can increase the risk of infections and other complications.
"Our goal is to develop a treatment that is both more effective and less toxic than current options," said Dr. Yang. "By targeting the specific cells that drive inflammation in RA, we can reduce the overall burden of the disease while minimizing side effects."
The study will involve preclinical testing of the targeted drug delivery systems in animal models of RA. The researchers will assess the ability of the nanoparticles to reduce inflammation, protect joints from damage, and improve overall function. If successful, the findings could pave the way for clinical trials in humans.
Rheumatoid arthritis is a chronic autoimmune disease that affects approximately 1% of the population worldwide. It causes inflammation of the joints, leading to pain, stiffness, and disability. Current treatments, such as methotrexate and TNF inhibitors, can effectively manage the symptoms of RA in many patients, but they are not always effective and can have significant side effects. The development of new, more targeted therapies is therefore a major unmet medical need.
